协同网络药理学:急性缺血性中风的临床前验证和临床安全
Ana I Casas1,2, Cristian Nogales2, Rebecca D Szepanowski1
1Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS) University Medicine Essen Essen Germany.
Journal of the American Heart Association
|May 15, 2025
概括
使用三重药物组合的新型网络药理方法显示,它对急性缺血性中风治疗具有前途. 这种基于机制的疗法是有效和临床安全的,目前正在进行二期试验.
科学领域:
- 系统医学和药理学.
- 神经科学和神经学是神经科学和神经学.
- 分子生物学分子生物学
背景情况:
- 传统的疾病定义缺乏分子基础,导致不准确的治疗方法.
- 系统医学通过分子机制 (风险基因,蛋白质,相互作用) 来定义疾病.
- 网络药理学提供了一种协同,多目标的方法来纠正疾病模块失调.
研究的目的:
- 在急性缺血性中风中测试网络药理原理.
- 开发一种基于机制的,对器官无关的中风治疗策略.
- 评估一种用于神经保护的新药组合的疗效和安全性.
主要方法:
- 将三个已验证的风险基因 (NOS1,NOX5,sGC) 扩展为一个单一的疾病模块.
- 利用C57/Bl6和人性化的NOX5敲入小鼠,诱导糖尿病以模拟中风并发症.
- 在临床前模型中使用三重药物组合 (NOX抑制剂,NOS抑制剂,sGC激活剂).
主要成果:
- 三重药物组合显著减少了小鼠心脏病发作的大小.
- 在糖尿病小鼠中,该组合预防了出血性转变.
- 在健康志愿者中进行的第一阶段试验证明了重新定位的药物的临床安全性.
结论:
- 基于机制的网络药理对于急性缺血性中风是有效的.
- 经过测试的方法在临床上是安全的,支持进一步的研究.
- 目前正在进行一项第一类神经保护性II期试验.
相关概念视频
Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K
Agonism and Antagonism: Quantification
296
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
296
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
432
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
432
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Combined Effects of Drugs: Antagonism
8.2K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
446
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
446


